.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,917,120

« Back to Dashboard

Claims for Patent: 4,917,120

Title: Nicotine impact modification
Abstract:Compositions comprising nicotine and a volatile nicotine-miscible substance may be used to create sources of modulated nicotine vapor. The modulation of nicotine vapor may be one of quantity or of perceived physiological impact or a combination of both. The substance should have a volatility somewhat similar to that of nicotine and have a normal boiling point between about 175.degree. C. and about 275.degree. C. These compositions may be placed in the nicotine reservoir of a personal oral nicotine inhaler. Esters are preferred nicotine miscible substances, particularly when substantially flavorless and generally recognized as safe for human consumption. Nicotine and nicotine-miscible substance in a weight/weight ratio between about 0.5 and 40.0 are emplaced in a nicotine reservoir, for example absorbed in a porous polyethylene item, for insertion into the tubular passageway of a smokeless cigarette.
Inventor(s): Hill; Ira D. (Locust, NJ)
Assignee: Advanced Tobacco Products, Inc. (San Antonio, TX)
Application Number:07/308,936
Patent Claims: 1. A smokeless nicotine inhaler consisting essentially of:

a housing having a first open end and a mouthpiece open end, said housing defining a tubular passageway between the first open end and the mouthpiece open end;

a reservoir in the passageway adapted to contain and liberate a volatile fluid comprising nicotine into air passing through said passageway, said reservoir being a porous solid-form synthetic polymer; and

a fluid contained in said reservoir, the fluid comprising nicotine and a volatile nicotine-miscible substance in a weight/weight ratio between about 2.0 and about 10.0, said volatile substance having a normal boiling point between about 175.degree. C. and about 275.degree. C.

2. The smokeless nicotine inhaler of claim 1 wherein the volatile nicotine-miscible substance is an ester.

3. The smokeless nicotine inhaler of claim 1 wherein the volatile nicotine-miscible substance accompanies nicotine vaporized from the reservoir and reduces sensory impact of vaporized nicotine on oral, pharyngeal or lung mucousal tissue.

4. The smokeless nicotine inhaler of claim 1 wherein the volatile nicotine-miscible substance is glyceryl triacetate.

5. The smokeless nicotine inhaler of claim 1 wherein the volatile nicotine-miscible substance is generally regarded as safe for human consumption.

6. The smokeless nicotine inhaler of claim 1 wherein the polymer is a polyolefin.

7. The smokeless nicotine inhaler of claim 1 wherein the polymer is polyethylene.

8. A smokeless nicotine inhaler consisting essentially of:

a housing having a first open end and a mouthpiece open end, said housing defining a tubular passageway between the first open end and the mouthpiece open end;

a porous solid-form polymeric reservoir contained in the passageway, said reservoir being adapted to contain volatile fluid and liberate the volatile fluid into air passing through said passageway; and

a fluid contained in said reservoir, the fluid consisting essentially of nicotine and a diol or triol at least partially esterified with an alkyl carboxylic acid having less than five carbon atoms to produce an ester having a normal boiling point between about 175.degree. C. and about 275.degree. C., the nicotine and ester being in a weight/weight ratio between about 0.5 and about 40.0.

9. A smokeless nicotine inhaler consisting essentially of:

a housing having a first open end and a mouthpiece open end, said housing defining a tubular passageway between the first open end and the mouthpiece open end;

a pourous solid-form polymeric reservoir contained in the passageway adapted to contain volatile fluid and liberate volatilized fluid into air passing through said passageway; and

a volatile fluid contained in said reservoir, the fluid consisting essentially of nicotine and an ester of ethanol with an alkyl carboxylic acid, the ester having a normal boiling point between about 175.degree. C. and about 275.degree. C., said nicotine and ester having a weight/weight ratio between about 0.5 and about 40.0.

10. A smokeless nicotine inhaler consisting essentially of:

a housing having a first open end and a mouthpiece open end, said housing defining a tubular passageway between the first open end and the mouthpiece open and;

a nicotine reservoir contained in the passageway to liberate nicotine into air passing through said passageway; and

a composition contained in said nicotine reservoir, the composition consisting essentially of nicotine and glyceryl triacetate in a weight/weight ratio between about 0.5 and about 40.

11. The smokeless nicotine inhaler of claim 10 wherein the fluid comprises nicotine and glyceryl triacetate in a weight/weight ratio between about 2 and about 10.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc